Jane Spencer

February 13, 2010 by admin  
Filed under Jane Spencer, Patients' stories

Standard Treatments Are Not Acceptable
Immunotherapy Can Boost Survivability

Jane Spencer suffered from a nonmucinous bronchioloalveolar adenocarcenoma of the lung. Utilizing the latest research and techniques, Dr. Smith was able to sucessfully treat not only Jane’s cancer, but also to improve her outlook on life.

A core controversy among oncologists continues over the validity and applicability of FDA approved treatment methods to the elderly or those with multisystem disease. Jane is an excellent example of the focus of this controversy.

We believe any assertion that proof of effecacy in young, high Karnovsky score patients is an appropriate indication for a more generalized use is specious. The older the patient, the more complicated the understanding and judgement required. Methods that extend life in the young may shorten life in the elderly. At best, generalizability is unproven.

Both sides of this controversy are presented in the attatched letters published in the journal CANCER, January 15, 2007.

Some important notes regarding Jane’s case:

The probability of dying in the 83rd year is 10%.
Jane had reached the age or rabidly accelerating risk of yearly death. The risk of death at age 93 is 23% / year
Elderly individuals do not tolerate cytotoxic chemotherapy well as compared with young adults.
Patients are more likely to die of “old age” as they reach the 80’s. Death by old age occurs when stem cell depletion occurs in vital organs sufficient to be incompatible with life. Thus, the Hayflick limit may indeed cause death by old age.
Jane presented with diffuse boney metastases on bone scan (see images). A sizable soft tissue protrusion on her scalp was caused by metastatic cancer to the calvarium (skull cap). Such advanced boney disease carries a poor prognosis with lung cancer.
Jane was treated with two cycles of standard cytoxic chemotherapy. The side effects were so debilitating that she decided against further chemotherapy of this kind. Jane presented after chemotherapy with a markedly elevated carcino embryonic antigen (CEA) of 435. CEA is a serologic marker for adenocarcinoma.
Under treatment with Tarceva, Xeloda, Zometa, cimetidine, anabolic hormones, several nutriceuticals (vitamin E, curcumin, selenium, etc), and low dose combination chemotherapy, there was a rapid and marked decline in her elevated CEA of 435 (see graph).

In spite of this apparent victory against the cancer, Jane developed a failure to thrive / wasting / sarcopenia syndrome. Possible causes included Tarceva (which was associated with persistent significant diarrhea), IL-2 (which may induce an anorexia malaise syndrome), and low dose chemo which, while far more tolerable than MTD (maximum tolerated dose) chemotherapy, may still contribute to a catabolic wasting syndrome.
Jane received fetal stem cell therapy under William Rader, MD in an attempt to restore her depleted stem cell reserves. Our strategy here was to circumvent the Hayflick limit. There was a gradual return in strength and stamina over successive months. Jane was placed on anabolic steroids and HGH to address the wasting pattern.

Jane’s treatment included protracted application of the IL-2 injection using the “belly plaque” technique.
At one year, Jane’s CEA remained in the normal range. She was able to host a bridge party for 8 at her house. She remained independent. In December, 2006 Jane received radiotherapy to her cervical spine for pain. This was the first palliative radiotherapy required.

Conclusion:

Jane was untreatable by conventional chemotherapy.

She would have died rapidly without successful intervention. Successful intervention necessitated a focused effort to “lean against” the generalized lean body wasting. Treatment of this wasting included intensive use of anabolic steroids (DHEA, 7-keto DHEA, pregnenolone, medroyprogesterone acetate and testosterone) as well as HGH.

Fetal stem cell therapy seems to have helped Jane revive her “joie de vivre”, improve her cognitive function, and reverse wasting / sarcopenia.

We believe that only by the judicious concurrent application of several efficacious strategies were we able to accomplish this sentinel superb result.

We believe patients should be free to choose the treatment method they wish after a rational analysis of the treatment options. Conventional care is often inadequate.

Dr. Smith has been honored by the several engineers and pharmacists who have sought his counsel. They have come only after careful due diligence study of their options. Dr. Smith’s father and four of his uncles were Georgia Tech engineers. Engineers have a rational, systematic perspective on reality. We are proud of Jane’s success, and doubly proud because we believe we understand the mechanisms by which her sustained remission was accomplished.

Comments are closed.